Berlex/Alliance Imavist
Executive Summary
Ultrasound contrast agent Imavist (perfluorohexane) could be approved for evaluation of cardiac function later this year, Alliance says, following submission of additional laboratory testing documentation in response to an Aug. 14, 2000 "approvable" letter from FDA; the agency cited chemistry, manufacturing and controls issues in the letter (1"The Pink Sheet" Aug. 28, 2000, In Brief). Final approval awaits a pre-approval inspection of Alliance's San Diego facility and labeling discussions. Launch is planned for first quarter 2002. Berlex will market the contrast agent
You may also be interested in...
Schering AG/Alliance Imavist
FDA deems cardiac ultrasound contrast agent "approvable" Aug. 14. Alliance said manufacturing and labeling issues need to be resolved before final approval. The NDA was submitted Oct. 13, 1999
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials